These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17680975)

  • 41. Lichenoid drug eruption related to imatinib: report of a new case and review of the literature.
    Sendagorta E; Herranz P; Feito M; Ramírez P; Feltes R; Floristán U; Mariño-Enriquez A; Casado M
    Clin Exp Dermatol; 2009 Oct; 34(7):e315-6. PubMed ID: 19456782
    [No Abstract]   [Full Text] [Related]  

  • 42. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
    Busuttil DP
    Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cutaneous reactions to imatinib mesylate treated by topical steroid.
    Ujiie H; Shimizu T; Shimizu H
    Am J Hematol; 2005 Mar; 78(3):246. PubMed ID: 15726597
    [No Abstract]   [Full Text] [Related]  

  • 44. [Imatinib-induced DRESS].
    Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
    Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX; Molimard M
    Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract]   [Full Text] [Related]  

  • 48. [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
    Zaritskiĭ AIu; Lomaia EG; Vinogradova OIu; Druzhkova GA; Kolosheĭnova TI; Loria SS; Pospelova TI; Krylova IV; Kruglov SS; Kuznetsov SV; Chelysheva EIu; Abakumov EM; Sokolova MA; Nemchenko IS; Zakharova ES; Goriacheva SR; Kolosova LIu; Vakhrusheva MV; Liamkina AS; Chernova OA; Machiulaĭtene ER; Ivanova VL; Udal'eva VIu; Shneĭder TV; Ogorodnikova IuS; Zhuravlev VS; Zakharova AV; Martynkevich IS; Domracheva EV; Afanas'ev BV; Abdulkadyrov KM; Kovaleva LG; Khoroshko ND; Turkina AG
    Ter Arkh; 2007; 79(8):17-22. PubMed ID: 17926465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple bowel perforations complicating imatinib treatment for advanced gastrointestinal stromal tumor.
    Chiarugi M; Galatioto C; Lippolis PV; Seccia M
    J Am Coll Surg; 2008 Feb; 206(2):386-7. PubMed ID: 18222396
    [No Abstract]   [Full Text] [Related]  

  • 50. Is imatinib-related cardiotoxicity still an open issue?
    Breccia M
    Leuk Res; 2011 Jan; 35(1):34-5. PubMed ID: 20961615
    [No Abstract]   [Full Text] [Related]  

  • 51. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec).
    Esmaeli B; Diba R; Ahmadi MA; Saadati HG; Faustina MM; Shepler TR; Talpaz M; Fraunfelder R; Rios MB; Kantarjian H
    Eye (Lond); 2004 Jul; 18(7):760-2. PubMed ID: 14739914
    [No Abstract]   [Full Text] [Related]  

  • 52. Gleevec may be heart toxic.
    Duke Med Health News; 2007 Jan; 13(1):2. PubMed ID: 17299882
    [No Abstract]   [Full Text] [Related]  

  • 53. Imatinib use during pregnancy and breast feeding: a case report and review of the literature.
    Ali R; Ozkalemkas F; Kimya Y; Koksal N; Ozkocaman V; Gulten T; Yorulmaz H; Tunali A
    Arch Gynecol Obstet; 2009 Aug; 280(2):169-75. PubMed ID: 19083009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
    Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
    Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
    Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
    Janssen JJ; Berendse HW; Schuurhuis GJ; Merle PA; Ossenkoppele GJ
    Am J Hematol; 2009 Oct; 84(10):679-82. PubMed ID: 19658186
    [No Abstract]   [Full Text] [Related]  

  • 57. Imatinib: the controversial discussion on cardiotoxicity induced by endoplasmic reticulum (ER) stress.
    Marchan R; Bolt HM
    Arch Toxicol; 2012 Mar; 86(3):339-40. PubMed ID: 22327847
    [No Abstract]   [Full Text] [Related]  

  • 58. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.
    Kiguchi T; Tauchi T; Ito Y; Miyazawa K; Kimura Y; Ohyashiki K
    Leuk Res; 2009 Mar; 33(3):506-8. PubMed ID: 18533259
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.
    Sillaber C; Mayerhofer M; Böhm A; Vales A; Gruze A; Aichberger KJ; Esterbauer H; Pfeilstöcker M; Sperr WR; Pickl WF; Haas OA; Valent P
    Eur J Clin Invest; 2008 Jan; 38(1):43-52. PubMed ID: 18173550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
    Kim M; Lee S; Jung CK; Lim J; Cho SG; Kim DW; Kim Y; Han K; Min WS; Kim CC
    Int J Lab Hematol; 2008 Dec; 30(6):508-12. PubMed ID: 18983302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.